US health regulators will fast-track new tests for fungal infections in lungs
What happened
The US Food and Drug Administration (FDA) has created a new, faster approval path for devices that detect fungal infections directly from lung samples. This means new diagnostic tests for serious lung infections can reach patients more quickly.
Why it matters
Before this, new tests for fungal infections had to go through a longer, more expensive approval process. This change means companies can now get these devices to market faster and with less regulatory burden. It should lead to more innovation and availability of these critical diagnostic tools.
The signal
Watch for an increase in the number of new fungal nucleic acid detection devices receiving FDA approval in the next 12-24 months.